Stock listing
TSXV:ARCH Arch Biopartners, Inc. Stock
Home listing (TSXV) of Arch Biopartners, Inc.
Follow Arch Biopartners, Inc. into a list and get an email when it puts out news.
Share price · TSXV:ARCH
$0.79 CAD -0.04 (-4.8%)
Close on Nov 2, 2026
- Day range
- $0.79 – $0.83 CADNov 2, 2026
- Volume
- 8,546 sharesNov 2, 2026
- Market cap
- $53.67M CADAt the close on Nov 2, 2026 · price × 67.93M shares outstanding
- 52-week range
- $0.39 – $1.45 CADLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $47,115 CADMedian day 29,000 shares · last 3 months, Aug 4, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSXV:ARCH · Home | $0.79 CAD | -0.04 (-4.8%) | 8,546 | $0.82 | $0.83 | $0.79 | $0.83 | Close on Nov 2, 2026 |
| OTC:ACHFF | $0.595 USD | 0.000 (0.0%) | — | $0.595 | $0.595 | $0.595 | $0.595 | Close on Oct 27, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 2, 2026 · TSXV:ARCH · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.79 | -0.04 | -4.8% | $0.82 | $0.83 | $0.79 | 8,546 | |
| $0.83 | +0.02 | +2.5% | $0.83 | $0.83 | $0.82 | 4,000 | |
| $0.81 | -0.01 | -1.2% | $0.86 | $0.87 | $0.81 | 14,000 | |
| $0.82 | -0.05 | -5.7% | $0.87 | $0.88 | $0.80 | 15,502 | |
| $0.87 | +0.01 | +1.2% | $0.86 | $0.87 | $0.85 | 3,500 | |
| $0.86 | -0.01 | -1.1% | $0.87 | $0.87 | $0.85 | 5,216 | |
| $0.87 | 0.00 | 0.0% | $0.86 | $0.87 | $0.85 | 6,500 | |
| $0.87 | -0.01 | -1.1% | $0.84 | $0.88 | $0.83 | 15,400 | |
| $0.88 | +0.03 | +3.5% | $0.88 | $0.88 | $0.83 | 11,500 | |
| $0.85 | +0.06 | +7.6% | $0.84 | $0.88 | $0.78 | 164,400 | |
| $0.79 | -0.09 | -10.2% | $0.81 | $0.82 | $0.79 | 23,500 | |
| $0.88 | +0.04 | +4.8% | $0.87 | $0.88 | $0.78 | 58,000 | |
| $0.84 | +0.01 | +1.2% | $0.83 | $0.86 | $0.83 | 15,500 | |
| $0.83 | -0.03 | -3.5% | $0.86 | $0.86 | $0.83 | 7,000 | |
| $0.86 | +0.03 | +3.6% | $0.85 | $0.86 | $0.79 | 13,400 | |
| $0.83 | -0.01 | -1.2% | $0.87 | $0.87 | $0.82 | 16,500 | |
| $0.84 | -0.01 | -1.2% | $0.87 | $0.87 | $0.82 | 12,500 | |
| $0.85 | -0.01 | -1.2% | $0.88 | $0.88 | $0.82 | 33,700 | |
| $0.86 | +0.03 | +3.6% | $0.83 | $0.86 | $0.82 | 9,000 | |
| $0.83 | 0.00 | 0.0% | $0.83 | $0.84 | $0.82 | 7,500 | |
| $0.83 | 0.00 | 0.0% | $0.87 | $0.87 | $0.83 | 3,800 | |
| $0.83 | -0.06 | -6.7% | $0.82 | $0.86 | $0.81 | 16,300 | |
| $0.89 | -0.01 | -1.1% | $0.87 | $0.89 | $0.82 | 142,900 | |
| $0.90 | +0.05 | +5.9% | $0.88 | $0.90 | $0.82 | 15,500 | |
| $0.85 | +0.01 | +1.2% | $0.88 | $0.89 | $0.78 | 59,200 | |
| $0.84 | -0.02 | -2.3% | $0.88 | $0.88 | $0.82 | 12,500 | |
| $0.86 | +0.05 | +6.2% | $0.87 | $0.87 | $0.79 | 40,000 | |
| $0.81 | -0.03 | -3.6% | $0.90 | $0.90 | $0.79 | 29,000 | |
| $0.84 | +0.03 | +3.7% | $0.81 | $0.845 | $0.76 | 123,500 | |
| $0.81 | -0.05 | -5.8% | $0.89 | $0.89 | $0.81 | 40,400 | |
| $0.86 | -0.06 | -6.5% | $0.93 | $0.93 | $0.84 | 53,200 | |
| $0.92 | +0.01 | +1.1% | $0.95 | $0.95 | $0.87 | 48,000 | |
| $0.91 | +0.02 | +2.2% | $0.96 | $0.96 | $0.87 | 47,500 | |
| $0.89 | -0.04 | -4.3% | $0.98 | $0.98 | $0.85 | 39,000 | |
| $0.93 | +0.01 | +1.1% | $0.89 | $0.93 | $0.86 | 33,500 | |
| $0.92 | +0.01 | +1.1% | $0.96 | $0.96 | $0.91 | 31,500 | |
| $0.91 | -0.05 | -5.2% | $0.95 | $0.98 | $0.86 | 113,500 | |
| $0.96 | 0.00 | 0.0% | $1.00 | $1.00 | $0.83 | 155,800 | |
| $0.96 | -0.06 | -5.9% | $1.06 | $1.06 | $0.94 | 60,400 | |
| $1.02 | -0.06 | -5.6% | $1.04 | $1.06 | $1.02 | 13,900 | |
| $1.08 | +0.05 | +4.9% | $1.01 | $1.08 | $0.99 | 10,900 | |
| $1.03 | +0.02 | +2.0% | $1.03 | $1.03 | $1.00 | 7,400 | |
| $1.01 | -0.02 | -1.9% | $1.05 | $1.06 | $0.99 | 93,100 | |
| $1.03 | -0.06 | -5.5% | $1.15 | $1.15 | $0.99 | 101,000 | |
| $1.09 | +0.14 | +14.7% | $1.00 | $1.09 | $0.90 | 245,400 | |
| $0.95 | -0.08 | -7.8% | $1.06 | $1.06 | $0.90 | 34,800 | |
| $1.03 | -0.04 | -3.7% | $1.09 | $1.09 | $0.98 | 31,800 | |
| $1.07 | -0.09 | -7.8% | $1.17 | $1.17 | $1.01 | 56,700 | |
| $1.16 | +0.04 | +3.6% | $1.14 | $1.16 | $1.10 | 10,300 | |
| $1.12 | +0.11 | +10.9% | $1.06 | $1.12 | $0.99 | 53,900 | |
| $1.01 | -0.09 | -8.2% | $1.09 | $1.09 | $0.96 | 65,500 | |
| $1.10 | -0.05 | -4.3% | $1.14 | $1.14 | $1.07 | 42,900 | |
| $1.15 | +0.06 | +5.5% | $1.12 | $1.15 | $1.09 | 5,800 | |
| $1.09 | -0.02 | -1.8% | $1.15 | $1.15 | $1.05 | 18,600 | |
| $1.11 | -0.04 | -3.5% | $1.22 | $1.22 | $1.11 | 24,400 | |
| $1.15 | +0.05 | +4.5% | $1.06 | $1.18 | $0.99 | 227,500 | |
| $1.10 | +0.01 | +0.9% | $1.09 | $1.18 | $1.05 | 41,400 | |
| $1.09 | -0.08 | -6.8% | $1.15 | $1.15 | $1.06 | 17,500 | |
| $1.17 | +0.11 | +10.4% | $1.06 | $1.17 | $1.05 | 73,400 | |
| $1.06 | +0.15 | +16.5% | $0.92 | $1.07 | $0.89 | 82,200 | |
| $0.91 | -0.02 | -2.2% | $0.94 | $0.94 | $0.89 | 26,200 | |
| $0.93 | +0.09 | +10.7% | $0.84 | $0.93 | $0.80 | 260,900 | |
| $0.84 | +0.03 | +3.7% | $0.88 | $0.88 | $0.83 | 9,600 |
- Ticker
- TSXV:ARCH
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSXV
- Currency
- CAD
What changed lately
Latest news release · Aug 31, 2026
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 28 slides
Latest news
Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
Aug 31, 2026
Closed $1.03 (-5.5%) on Aug 31, 2026
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
Aug 11, 2026
Closed $1.09 (-6.8%) on Aug 11, 2026
Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program
Jul 17, 2026
Closed $0.84 (-1.2%) on Jul 17, 2026
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Jun 4, 2026
Closed $0.52 (+9.5%) on Jun 4, 2026
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
May 22, 2026
Closed $0.445 (0.0%) on May 22, 2026
Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI
Apr 30, 2026
Closed $0.435 (0.0%) on Apr 30, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Mar 24, 2026
Closed $0.57 (-5.0%) on Mar 24, 2026
Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Mar 20, 2026
Closed $0.57 (-12.3%) on Mar 20, 2026
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Feb 9, 2026
Closed $0.79 (+1.3%) on Feb 9, 2026
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board
Jan 16, 2026
Closed $1.38 (+0.7%) on Jan 16, 2026
Decks
Investor Presentation (October 2026)
Investor deck · 28 slides · October 2026
Investor Presentation (September 2026)
Investor deck · 28 slides · September 2026
Investor Presentation (August 2026)
Investor deck · 28 slides · August 2026
Investor Presentation (July 2026)
Investor deck · 28 slides · July 2026
Arch Biopartners, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 24 in all · newest Aug 31, 2026 · oldest 2009
- Decks
- 23 decks · latest October 2026
Where Arch Biopartners, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSXV:ARCH · Home listing · This page | TSXV | Canada | CAD |
| Cboe Canada:ARCH | Cboe Canada | Canada | CAD |
| OTC:ACHFF | OTC | United States | USD |
| Frankfurt:8HA | Frankfurt | Germany | EUR |
Log in to ask 6ix AI your own questions about Arch Biopartners, Inc.